← Human Trials & Peer-Reviewed Studies
Growth hormone (GH)-binding protein regulation by estrogen, progesterone, and gonadotropins in human: the effect of ovulation induction with menopausal gonadotropins, GH, and gestation.
Plain-language guide to PMID 1430084 (1992): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 26 patients.
Key Facts
- PMID
- 1430084
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1992
- Study type
- Randomized Controlled Trial
- Authors
- Blumenfeld Z et al. (5 authors)
- DOI
- 10.1210/jcem.75.5.1430084
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin).
To assess the serum GH-BP levels under various physiological and supraphysiological levels of sex steroids, the researchers have evaluated its concentration in 26 patients undergoing 34 cycles of ovulation induction with either human menopausal gonadotropins (hMG)/hCG or GH/hMG/hCG.
Why It Was Studied
The recently described serum GH-binding protein (GH-BP) may reflect the GH-receptor level.
The latter ovulation induction protocol was undertaken in "Clonidine negative" patients in a prospective, randomized, crossed-over manner, between GH/hMG/hCG or hMG/hCG.
Who Took Part
The study group was 26 patients.
PubMed tags the participants as women only.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
What Was Measured
The recently described serum GH-binding protein (GH-BP) may reflect the GH-receptor level.
PubMed files the paper under topics including Carrier Proteins, Chorionic Gonadotropin, Estrogens, Gonadotropins, Growth Hormone, Menotropins and Ovulation Induction.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and hCG (human chorionic gonadotropin) in 26 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1992 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the hCG (human chorionic gonadotropin) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
hCG (human chorionic gonadotropin): An LH analog that drives Leydig-cell testosterone production.
HMG (Human Menopausal Gonadotropin): Menotropins: a glycoprotein preparation that supplies follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- hCG (human chorionic gonadotropin) in the library
- HMG (Human Menopausal Gonadotropin) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.